Melatonin: What It’s Actually Studied For (and Why US Doses Are Often Far Higher Than the Research)

Melatonin is the most widely used sleep supplement in the United States, sold as tablets, capsules, gummies, and sprays in doses from under 1 mg to 10 mg or more. It’s also one of the more misunderstood ones: it’s a hormone, not a sedative, and the research behind it splits cleanly into two different questions that get marketed as one.

Here’s what we found separating them, including where the evidence for “just take less” is more complicated than it first appears.

The short version

• Melatonin has its best evidence for circadian-timing problems — jet lag and delayed sleep-wake phase disorder (a body clock that runs hours later than a normal schedule). For delayed sleep-wake phase disorder, the American Academy of Sleep Medicine (AASM) actually recommends melatonin, timed to the body clock rather than to bedtime — though it’s a weak recommendation, with acknowledged uncertainty about whether benefits outweigh harms.
• For general chronic insomnia unrelated to circadian timing — which is how melatonin is mostly bought and sold in the US — the same AASM guideline recommends against using it. That’s also a weak recommendation, reflecting evidence the guideline panel judged too thin to support routine use either way.
• The largest meta-analysis of melatonin for sleep pooled 19 trials in 1,683 people and found modest benefits: falling asleep about 7 minutes faster and sleeping about 8 minutes longer than placebo. But that analysis mixed insomnia and circadian-disorder trials together, and — a complication we’re not going to smooth over — it found higher doses and longer treatment duration were associated with larger effects, not smaller ones. That cuts against a simple “lower doses work just as well” story.
• The cleaner case for lower doses comes from a different, narrower body of research: studies measuring what dose of melatonin actually reproduces the body’s own natural nighttime blood levels. That work, done specifically in adults 55 and older, concludes the lowest effective dose is best because higher doses push blood melatonin well above what the body would ever produce on its own.
• Independent of effectiveness, there’s a real quality-control problem: analyses of commercial melatonin products have repeatedly found labeled and actual content don’t match, sometimes by a wide margin, and gummies in particular have driven a sharp rise in accidental pediatric ingestions serious enough to need emergency care.

Our evidence rating for melatonin is not one verdict — this is a case where the indication matters more than the ingredient. See the ratings section near the end.

What melatonin is actually studied for

Melatonin is a hormone the brain produces in response to darkness, largely from the pineal gland, and it’s central to timing the body’s circadian rhythm rather than to sedation itself. Most of the higher-quality trial evidence targets problems with the timing of sleep, not sleep in general.

Jet lag

Crossing multiple time zones disrupts the body clock’s alignment with the local light-dark cycle, causing the cluster of symptoms known as jet lag: poor sleep, daytime fatigue, impaired functioning, and sometimes digestive upset.

According to a synthesis of two mid-sized systematic reviews (2010 and 2014) summarized by the National Center for Complementary and Integrative Health (NCCIH), four studies totaling 142 travelers found melatonin outperformed placebo on jet lag symptoms after eastward flights, and a separate study of 234 travelers found low-quality evidence of a sleep-quality benefit on eastward flights specifically. Two further studies totaling 90 travelers found a benefit after westward flights. We’re relying on NCCIH’s synthesis of the underlying Cochrane review here rather than having independently read the full Cochrane text ourselves — flagged below in the editorial notes.

Delayed sleep-wake phase disorder (DSWPD)

People with DSWPD have body clocks that run persistently later than a conventional schedule — typically unable to fall asleep before 2–6 a.m. and preferring to wake between 10 a.m. and 1 p.m. This is a circadian rhythm disorder, not garden-variety insomnia, and it’s diagnosed rather than self-identified.

This is the specific condition where the evidence is strong enough that a clinical body has weighed in affirmatively. The 2015 AASM clinical practice guideline for circadian rhythm sleep-wake disorders recommends melatonin, timed to the individual’s circadian phase rather than to a fixed bedtime, for DSWPD — a weak recommendation, with the guideline itself flagging uncertainty about whether the benefits clearly outweigh the risks. A 2018 randomized trial of 307 people with DSWPD (published after that guideline) found that melatonin taken an hour before the desired bedtime, combined with a fixed wake time, produced meaningful improvements: falling asleep about 34 minutes earlier on average, along with better sleep in the first third of the night and better daytime functioning.

General chronic insomnia — the use case it’s mostly sold for

This is where the marketing and the guidance diverge most. Two major clinical practice guidelines have weighed in on melatonin for ordinary chronic insomnia not tied to circadian timing: the 2017 AASM guideline and the 2016 American College of Physicians guideline. Both concluded there isn’t enough strong evidence on melatonin’s effectiveness or safety for chronic insomnia to recommend its use — the AASM guideline’s language is a recommendation against using it, again graded weak.

The largest single meta-analysis on melatonin and sleep, published by Ferracioli-Oda, Qawasmi and Bloch in PLoS ONE in 2013, pooled 19 randomized placebo-controlled trials covering 1,683 subjects — 14 trials in insomnia, 4 in DSWPD, and 1 in REM sleep behavior disorder, combined into a single analysis rather than reported separately by condition. Pooled across that mixed population, melatonin reduced sleep onset latency by 7.06 minutes (95% CI: 4.37–9.75, p<0.001), increased total sleep time by 8.25 minutes (95% CI: 1.74–14.75, p=0.013), and modestly improved a composite sleep-quality measure (standardized mean difference 0.22, 95% CI: 0.12–0.32, p<0.001). The authors’ own conclusion: the effects are real but modest, and don’t seem to fade with continued use — but they’re smaller than what’s typically seen from prescription insomnia medications. One author disclosed research fellowship funding tied to Eli Lilly, a pharmaceutical company that sells prescription sleep and psychiatric medications; the paper’s own funding statement says none of its funders, including that one, had a role in study design, analysis, or the decision to publish. We mention it because our Editorial Policy says we will, not because it changes the numbers above.

The complication we want to be direct about: this same meta-analysis found, via meta-regression, that trials using higher doses and longer treatment duration reported larger effects on sleep latency (trend-level, p=0.05) and total sleep time (p=0.007) — not smaller ones. Dose and duration had no significant effect on the sleep-quality measure either way. That finding runs against a simple “lower doses are just as effective for insomnia” narrative, and we’re not going to pretend it doesn’t exist because it complicates this article’s own title.

The dose-mismatch question — where the evidence for “less is more” actually comes from

The idea that commercial melatonin doses run far above what’s useful is common in health journalism, and it isn’t baseless — but the strongest version of that case isn’t about insomnia outcomes. It’s about matching the hormone’s own physiology.

A 2014 systematic review by Vural, van Munster and de Rooij in Drugs & Aging set out specifically to determine what dose of exogenous melatonin best reproduces natural nighttime melatonin levels in adults aged 55 and older. Its conclusion: clinicians should use the lowest possible dose of an immediate-release formulation, because that best mimics the body’s own physiological circadian rhythm — and because higher doses risk prolonged, supra-physiological blood levels that go well beyond what the body would ever produce naturally. That’s a real and citable basis for “less is often enough,” but it’s a conclusion about matching physiology in an older-adult population specifically, not a head-to-head finding that higher doses fail to help with sleep symptoms generally — the Ferracioli-Oda meta-regression above suggests the opposite for insomnia-latency outcomes.

Set against that physiological argument, retail melatonin in the US commonly comes in doses at or above what circadian-timing protocols actually use. A 2023 study by Cohen and colleagues, published in JAMA, measured the actual melatonin content of 25 commercially available gummy products in the US and found actual per-serving content ranging from 1.3 mg to 13 mg — and in 22 of the 25 products, that measured amount didn’t match the label, most often running higher (74% to 347% of the labeled amount). For comparison, the jet lag and DSWPD protocols described above mostly used doses in the roughly 0.5–5 mg range.

So the honest version of the dose story has two separate strands: a physiological argument (from research in older adults) that lower doses better match the body’s own hormone levels and avoid unnecessary supra-physiological exposure, and a completely separate, unrelated problem that a meaningful share of commercial products don’t reliably deliver the dose printed on the label in the first place — which makes “just take a lower dose” harder to act on than it sounds, since the label may not be trustworthy regardless of what number is printed on it.

What we could not check

• We did not independently read the full Cochrane jet lag review. The jet lag figures above come from NCCIH’s published synthesis of that review, not from our own read of the Cochrane text — a lower bar of verification than we held the magnesium article to, and worth naming rather than hiding.
• We did not test any product. We have no independent data on what’s actually in any specific melatonin product sold today; the label-accuracy figures above are from the cited studies’ own product samples (Erland & Saxena’s 2017 sample of 31 products; Cohen et al.’s 2023 sample of 25 gummies), not a survey we ran.
• We could not resolve the dose question into a single number. The circadian-timing literature and the general-insomnia meta-analysis point in different directions on dose, and we don’t think a single “ideal mg” figure can honestly be extracted from the evidence as it currently stands.
• We did not evaluate children’s dosing. NCCIH’s own review flags substantial uncertainty about melatonin’s effects on children’s hormonal development; that’s a distinct topic from the adult-focused claims in this piece and would need its own dedicated treatment, not a subsection here.

Safety and quality-control issues, separate from effectiveness

Product content doesn’t reliably match the label. A 2017 analysis by Erland and Saxena in the Journal of Clinical Sleep Medicine tested 31 melatonin products from 16 brands and found that more than 70% fell outside a 10% margin of their labeled content, with actual content ranging from 83% below to 478% above the label claim; lot-to-lot variability within the same product reached as much as 465%. The same study found unlabeled serotonin in 26% of tested products, mostly those combining melatonin with herbal extracts.

Pediatric ingestion has risen sharply, and gummies are a specific driver. Per two CDC MMWR reports, annual pediatric melatonin ingestions reported to US poison control centers rose from 8,337 in 2012 to 52,563 in 2021 — a 530% increase — with hospitalizations and serious outcomes also increasing over that period. A more recent CDC report estimated roughly 11,000 emergency department visits during 2019–2022 for unsupervised melatonin ingestion by children aged 5 and under, disproportionately involving flavored gummy products; in more than a third of solid-dose visits, the child had ingested 10 or more units.

Regulatory status. In the US, melatonin is regulated as a dietary supplement, meaning it faces substantially less premarket scrutiny from the FDA than a prescription or over-the-counter drug — it does not need to demonstrate effectiveness or a validated manufacturing standard before going on shelves. NCCIH notes that in several other countries, melatonin is available only by prescription and is regulated as a drug.

Who should talk to someone first

Melatonin interacts with some medications and carries specific caution for a few groups. Per NCCIH, people taking blood thinners or with epilepsy should be under medical supervision if using melatonin supplements. There’s a documented lack of research on melatonin’s safety in pregnancy and breastfeeding. Older adults may retain melatonin longer than younger adults, raising the risk of daytime drowsiness, and the 2015 AASM circadian-rhythm guideline specifically recommends against melatonin use in people with dementia.

For children, NCCIH’s own guidance is to talk to a pediatrician before giving a child melatonin for sleep — not because short-term use at normal doses appears unsafe in the studies available, but because there are meaningfully fewer studies, and because melatonin is a hormone with theoretical (not yet resolved) implications for puberty and other hormonal development.

Nothing here is medical advice, and no one on our team is a clinician. That’s stated plainly on our About page.

Our rating, and why

We’re not giving melatonin one rating, because the evidence genuinely differs by what it’s being used for — collapsing that into a single badge would misrepresent both halves.

For circadian-timing indications (jet lag, delayed sleep-wake phase disorder): Moderate. Under our evidence scale, this reflects a real body of trial evidence and, for DSWPD specifically, an affirmative (if weak) recommendation from a major clinical guideline body. It is not “Strong” — the AASM’s own recommendation is graded weak, reflecting real uncertainty about the balance of benefit and harm, and we relied on a secondary synthesis rather than a first-hand read of the full Cochrane jet lag review.

For general chronic insomnia unrelated to circadian timing — the use case behind most retail marketing: Limited. The largest pooled analysis shows a real but modest effect, and two major clinical guidelines (AASM 2017, ACP 2016) recommend against routine use given the overall strength of the evidence. This is also the rating that best reflects the article’s own most important caveat: the same meta-analysis that shows a modest benefit also shows that benefit trending larger, not smaller, at higher doses — which undercuts the tidy “you just need less” framing this piece set out to test.

If the research on either question develops further, these ratings will change, and we’ll say so on this page when they do.

Sources

1. National Center for Complementary and Integrative Health (NCCIH). Melatonin: What You Need To Know. Last updated May 2024. https://www.nccih.nih.gov/health/melatonin-what-you-need-to-know
2. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. PLoS ONE. 2013;8(5):e63773. https://doi.org/10.1371/journal.pone.0063773
3. Auger RR, Burgess HJ, Emens JS, et al. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced sleep-wake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep-wake rhythm disorder (ISWRD). Journal of Clinical Sleep Medicine. 2015;11(10):1199-1236.
4. Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine. 2017;13(2):307-349.
5. Qaseem A, Kansagara D, Forciea MA, et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine. 2016;165(2):125-133.
6. Vural EMS, van Munster BC, de Rooij SE. Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature. Drugs & Aging. 2014;31(6):441-451.
7. Erland LAE, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. Journal of Clinical Sleep Medicine. 2017;13(2):275-281. https://jcsm.aasm.org/doi/10.5664/jcsm.6462
8. Cohen PA, Avula B, Wang Y-H, et al. Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. JAMA. 2023;329(16):1401-1402.
9. Lelak K, Vohra V, Neuman MI, et al. Pediatric melatonin ingestions — United States, 2012–2021. MMWR Morbidity and Mortality Weekly Report. 2022;71(22):725-729.
10. Freeman DI, Lind JN, Weidle NJ, et al. Notes from the field: emergency department visits for unsupervised pediatric melatonin ingestion — United States, 2019–2022. MMWR Morbidity and Mortality Weekly Report. 2024;73(9):215-217.